Prof Vera Bittner (University of Alabama at Brimingham, Birmingham, AL,US) discusses the ODYSSEY OUTCOMES Trial - Lipoprotein(a) lowering by alirocumab contributes to total events reduction independent of LDL cholesterol.
Filmed on site at ACC 2019 by Radcliffe Cardiology
1. Please remind us of the ODYSSEY trial and its key findings?
2. What was the rationale for this sub-analysis and how was it conducted?
3. What does this mean for clinical practice?
4. What else should be anticipated from the ODSYSEY programme?
Videography: Josh Birch
Interviewer: Liam O’Neill